Achaogen (AKAO) Secures Max $18M Contract from BARDA for Support Development of Orally-Administered Antibacterial Candidate C-Scape
Tweet Send to a Friend
Achaogen, Inc. (NASDAQ: AKAO) today announced that it has been awarded a contract valued at up to $18 million in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
